The GLP is committed to full transparency. Download and review our 2019 Annual Report

Gene therapy’s breakout moment

| March 7, 2013
This article or excerpt is included in the GLP’s daily curated selection of ideologically diverse news, opinion and analysis of biotechnology innovation.

The following is an excerpt.

Venture capital interest in funding gene therapies and the companies that develop them has dramatically increased judging by a recent spurt of activity, a lot of due diligence, a few deals announced, and a few more in the works and expected to be announced soon.

What does all that activity mean? First, there’s enough clinical data out there to validate the concept of gene therapy. The more speculative venture capital investors, rather than the pharmaceutical industry, are realizing the potential of this and are getting into the game.

View the original article here: Is This Gene Therapy’s Breakout Moment?

Additional resources:

The GLP featured this article to reflect the diversity of news, opinion and analysis. The viewpoint is the author’s own. The GLP’s goal is to stimulate constructive discourse on challenging science issues.

News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.

Send this to a friend